We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,335.00 | 1,333.50 | 1,334.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.22 | 55.34B |
Date | Subject | Author | Discuss |
---|---|---|---|
25/10/2007 11:11 | The recovery has began I just saw it go up a penny, honest. | mikejay | |
25/10/2007 10:59 | Fantastic recovery ... by the FTSE over 80 points up. | mikejay | |
25/10/2007 10:04 | When oils and miners correct more defensive stocks like GSK will become more attractive | ok,yah | |
25/10/2007 09:27 | I agree - Avandia is yesterday's news - pharma companies just not flavour of the month/year... | eisler | |
25/10/2007 08:58 | I don't think this is an Avandia issue anymore... big pharma are out of favour currently and their results and business model are uninspiring, add to that a near zero chance of a private equity take out given the huge market caps and the credit crunch, kind of explains the low rating. let's not also forget that GSK's top man (literally) JP Garnier is off next year and the bland internally promoted successor has a lot to do, the Market will wait to see what strategy he will adopt before re-rating the shares.. the shares are likely to trade in a range between 1200-1300 ceteris paribus... the buyback is the only thing that is keeping the share price up above the key 1200-1215 level All IMHO. | gbchak | |
25/10/2007 08:12 | wonder when the market will wake up to the fact that glaxo is priced as if avandia didn't exist? 5.5 billion turnover was pretty good imo More imortantly the pipeline of drugs looks better than for years | taffee | |
25/10/2007 07:48 | An unexpected drop this morning. Hopefully recover by the day end. | sat69 | |
24/10/2007 20:33 | With the DOW showing a reversal of over 100 points. We should be turning blue tomorrow. Good luck guys | sat69 | |
24/10/2007 20:31 | Closed today at 1249p - It's all upside from here. | sat69 | |
24/10/2007 20:30 | Future Key Dates hxxp://www.gsk.com/e 27 October 2021 Announcement of Q3 2021 results 9 February 2022 Announcement of Q4 2021 results !FOLLOWFEED | sat69 | |
24/5/2007 11:56 | RFV may45 I'm waiting too, more support at this level from squiggles than 1308 but almost 10% discount from last peak. Am tempted! | edjgee | |
24/5/2007 10:34 | may45 - IMHO 1326 0r even 1308 | rfv | |
24/5/2007 08:52 | buy at now or waiting more times to ... ? please commm.... | may45 | |
23/5/2007 00:21 | Don`t forget the democrats are determined to drive drug prices down in the USA - This latest fiasco is all grist to the mill for them. It`s shooting season for the BIG pharmas! | freds13 | |
23/5/2007 00:00 | Exactly, Mr accumulator. | jonak | |
22/5/2007 11:00 | "Our study has important limitations. We pooled the results of a group of trials that were not originally intended to explore cardiovascular outcomes. Most trials did not centrally adjudicate cardiovascular outcomes, and the definitions of myocardial infarction were not available. Many of these trials were small and short-term, resulting in few adverse cardiovascular events or deaths. Accordingly, the confidence intervals for the odds ratios for myocardial infarction and death from cardiovascular causes are wide, resulting in considerable uncertainty about the magnitude of the observed hazard. Furthermore, we did not have access to original source data for any of these trials. Thus, we based the analysis on available data from publicly disclosed summaries of events. The lack of availability of source data did not allow the use of more statistically powerful time-to-event analysis. A meta-analysis is always considered less convincing than a large prospective trial designed to assess the outcome of interest. Although such a dedicated trial has not been completed for rosiglitazone, the ongoing Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) trial may provide useful insights." Also, GSK have publicly stated that they are willing and happy to work with the reports authors. i'd say that suggests that they are confident in their ongoing trials results. | accumulator | |
22/5/2007 10:13 | Yes it went ex-div on 2nd May | gateside | |
22/5/2007 08:00 | Is this share ex dividend yet for this quarter? Shades of AZN with its statin drug! Might be a money spinner with correct entry 1330 1310 or do you think lower anyone? Freds13, know the feeling used work with that stuff daily! | edjgee |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions